Key Updates in the Health Sector: Marketplace Moves and Medical Advances

Recent health news include Mallinckrodt's sale of Therakos unit for $925 million, GSK's trial victory over Zantac cancer claims, the competition between Eli Lilly and Novo Nordisk in the weight-loss market, a lawsuit against Novartis and Viatris over HeLa cells, Tenet's sale of five hospitals, BioNTech's financial shift to cancer drugs, stress experienced by triathletes in the Seine, FDA approval of Adaptimmune's cancer therapy, and Neuralink's brain chip implant in a second trial patient.

Mallinckrodt is selling its Therakos business to CVC Capital Partners for $925 million to significantly reduce debt, following the $1.33 billion purchase in 2015. GSK emerged victorious in a court trial involving Zantac cancer claims, with a jury ruling in favor of the company.

Eli Lilly's Zepbound is competing strongly with Novo Nordisk's Wegovy for U.S. weight-loss market share. Meanwhile, Novartis and Viatris face legal issues over the alleged unauthorized use of cellular material from Henrietta Lacks in their drug development.

Tenet Healthcare plans to sell its majority stake in Brookwood Baptist Health for $910 million to Orlando Health. German drugmaker BioNTech reported significant second-quarter losses but is focusing on developing new cancer treatments. Triathletes experienced stress due to water quality concerns in the Seine during the Olympics, despite French authorities' efforts to improve conditions.

The FDA has approved Adaptimmune's new cancer therapy Tecelra for synovial sarcoma. Additionally, Neuralink, Elon Musk's venture, has successfully implanted its brain chip in a second patient.

(With inputs from agencies.)